See the DrugPatentWatch profile for Evkeeza
What approvals does Evkeeza have, and where is it approved?
Evkeeza (evinacumab-dgnb) is an FDA-approved medicine for treating certain forms of familial hypercholesterolemia (FH) and related lipid disorders. It is approved for adults and is used when LDL cholesterol remains high despite other therapies [1].
How was Evkeeza approved by the FDA?
Evkeeza’s FDA approval was based on clinical trial evidence showing reductions in LDL cholesterol in people with familial hypercholesterolemia, including patients who have not reached target LDL levels with existing treatments [1].
What condition does Evkeeza target?
Evkeeza is designed to lower LDL cholesterol by targeting the ANGPTL3 pathway, which helps reduce cholesterol production and/or increase clearance mechanisms involved in LDL cholesterol levels [1].
When was Evkeeza approved (FDA approval date)?
Evkeeza’s FDA approval date is listed in FDA labeling and related public FDA materials as part of its regulatory approval history [1].
What do patients usually ask after approval: who can get it and how is it used?
After approval, the key practical questions are usually eligibility (which FH or lipid conditions qualify), dosing schedule, and whether it is used alone or alongside other lipid-lowering therapies. The approved indications and dosing details are provided in the official prescribing information [1].
Where to check the latest approval/label updates
For the most current approved uses (and any label changes), the most reliable sources are the FDA prescribing information and FDA communications for Evkeeza [1].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761168